Table 1. Characteristics of studies, HIV-infected adults and follow-up without antiretroviral treatment (ART) in West Africa, ANRS 12222 Morbidity/Mortality Collaboration.
| 1 | 2 | 3 | 4 | 5 | Overall | |
|---|---|---|---|---|---|---|
| Country | Côte d'Ivoire | Côte d'Ivoire | Burkina Faso | Côte d'Ivoire | Côte d'Ivoire | - |
| Study Period | 1996-2003 | 1997-2009 | 1998-2008 | 2000-2005 | 2003-2008 | - |
| Main inclusion criteria | Adults, WHO stage 2-3 |
Adults recent seroconversion | Women ≥ 15 years, sex workers | Pregnant women | Pregnant and post-partum women and their family | - |
| Main outcome | Natural history | Natural history | Sexual transmitted infections | Tolerance, efficacy of pMTCT | Pilot ART program | - |
| Number of participants | 719 | 275 | 256 | 709 | 974 | 2588* |
| Baseline characteristics | ||||||
| Women, % | 69 | 40 | 100 | 100 | 88 | 80§ |
| Median age, years (IQR) |
31 | 29 | 31 | 27 | 29 | 29 |
| (26-37) | (25-34) | (25-38) | (23-30) | (25-33) | (25-34) | |
| Median CD4 count/mm3 (IQR) |
297 | 470 | 364 | 544 | 363 | 395 |
| (156-511) | (331-645) | (218-568) | (348-756) | (231-539) | (234-612) | |
| WHO stage 3 or 4, % | 56 | 0 | 24 | 25 | 22 | 30 |
|
| ||||||
| Follow-up characteristics | ||||||
|
| ||||||
| Median follow-up, years, (IQR) | 3.1 | 4.2 | 1.8 | 1.8 | 1.5 | 1.9§ |
| (1.5-5.2) | (2.4-6.1) | (0.8-4.1) | (1.7-1.8) | (0.1-3.0) | (1.1-4.1) | |
| Number of CD4 count per patient, median (IQR) |
5 | 8 | 3 | 3 | 2 | 4#,§ |
| (2-8) | (4-12) | (2-6) | (2-4) | (1-6) | (2-7) | |
|
| ||||||
| Person-years of follow-up | ||||||
| Overall | 2336 | 1217 | 565 | 1022 | 1722 | 6862§ |
| Per CD4 stratum /mm3** | ||||||
| 0-50 | 99 | 1 | 0 | 0 | 0 | 100 |
| 51-100 | 175 | 3 | 5 | 6 | 3 | 194 |
| 101-200 | 514 | 69 | 30 | 58 | 23 | 693 |
| 201-350 | 623 | 355 | 172 | 212 | 320 | 1684 |
| 351-500 | 377 | 365 | 135 | 205 | 499 | 1580 |
| 501-650 | 250 | 243 | 111 | 241 | 409 | 1254 |
| >650 | 297 | 181 | 111 | 300 | 467 | 1357 |
| Status at study termination, % | ||||||
| Alive without ART | 29 | 43 | 41 | 89 | 37 | 40 |
| ART initiation | 19 | 38 | 40 | 0 | 43 | 31 |
| Lost to follow-up | 8 | 12 | 12 | 9 | 19 | 14 |
| Dead | 43 | 7 | 6 | 2 | 2 | 15 |
*
345 participated both to studies 4 and 5;
**
modelized
#
During follow-up, 312 patients (12%) had at least one CD4 count missing, including 107 with only one missing CD4 count and 205 with >1 missing CD4 count
§
1307 women were pregnant at study entry or became pregnant during follow-up. The median time of follow-up during pregnancy was 0.4 year (IQR : 0.3-0.5), and the median number of CD4 measurements during pregnancy was 1 (IQR: 0-1). Overall follow-up during pregnancy was 605 person-years, representing 9% of the total follow-up in the study.
- ART: antiretroviral treatment; pMTCT: Prevention of Mother to Child Transmission; IQR: interquartile range